IP Verse

Greiner patent opposition analysis

Law FirmOpposition Filing Analysis

The comprehensive analysis of Greiner opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Greiner

Patent Number	Title	Applicant	Opposition Date	Opposition Company
EP4321157	New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)	NOVARTIS	Jun 25, 2025	ZENTIVA KS
EP3815688	Pharmaceutical Composition Containing Poorly-Soluble Basic Medicine	CHUGAI SEIYAKU KABUSHIKI KAISHA	Sep 6, 2024	SANDOZ
EP3626270	New Use	NOVARTIS	Jul 11, 2024	ZENTIVA KS
EP3294283	Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure	NOVARTIS	Dec 8, 2023	ZENTIVA
EP3345607	Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or Agonist	OSSIFI MAB	Jul 26, 2023	AMGEN EUROPE
EP2959894	S1P Receptor Modulators For Treating Multiple Sclerosis	NOVARTIS	Nov 21, 2022	A MED
EP2959894	S1P Receptor Modulators For Treating Multiple Sclerosis	NOVARTIS	Oct 12, 2022	ZENTIVA KS
EP3548000	Atropine Pharmaceutical Compositions	NEVAKAR	Aug 9, 2022	PHARMA STULLN
EP3464373	Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer	BRISTOL MYERS SQUIBB	Jul 27, 2022	GREINER
EP3426226	Ophthalmological Composition	URSAPHARM ARZNEIMITTEL	Jun 9, 2022	PHARMA STULLN

Top companies who are the clients of Greiner

Company	Total
ZENTIVA	6
GREINER	6
TEVA PHARMACEUTICALS	4
ZENTIVA KS	4
DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBB	3
SANDOZ	2
PHARMA STULLN	2
HEXAL	1
AMGEN	1
AMGEN EUROPE	1